Plain-English translation of NCT06675864 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new experimental medication called YTB323 for people with progressive multiple sclerosis (a form of MS where symptoms gradually worsen over time). The trial is designed to find out whether the medication is safe and how the body responds to it. All participants will receive the medication, and researchers will carefully monitor them to watch for side effects and any changes in their disease.
Progressive MS is harder to treat than other forms of multiple sclerosis, and people with this type need new treatment options. This trial is exploring whether this new medication could help slow disease progression and be a safe option for patients.
You likely qualify if…
You likely don't qualify if…
You will receive one dose of YTB323 as an infusion. The trial spans 2 years of active monitoring, during which you will have multiple visits for blood tests, spinal fluid sampling, MRI scans of your brain and spine, and other checkups to track how your body responds to the treatment. After the initial 2 years, you will be asked to participate in long-term follow-up visits for an additional 13 years to ensure your safety and monitor any long-term effects.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Australia
Canada
France